Last reviewed · How we verify
Dactavira Plus
Dactavira Plus is a direct-acting antiviral combination therapy designed to inhibit hepatitis C virus replication through multiple viral targets.
Dactavira Plus is a direct-acting antiviral combination therapy designed to inhibit hepatitis C virus replication through multiple viral targets. Used for Hepatitis C virus infection (genotype unspecified).
At a glance
| Generic name | Dactavira Plus |
|---|---|
| Sponsor | Egyptian Liver Hospital |
| Drug class | Direct-acting antiviral (DAA) combination |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | Phase 3 |
Mechanism of action
The drug combines antiviral agents that target different steps of the hepatitis C virus lifecycle, likely including NS5B polymerase and/or protease inhibitors. By hitting multiple viral targets simultaneously, the combination approach aims to improve efficacy and reduce the risk of resistance development in hepatitis C patients.
Approved indications
- Hepatitis C virus infection (genotype unspecified)
Common side effects
- Headache
- Fatigue
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dactavira Plus CI brief — competitive landscape report
- Dactavira Plus updates RSS · CI watch RSS
- Egyptian Liver Hospital portfolio CI